Recorded live on Thursday, May 27, 2021 • Hosted by AST's Community of Transplant Scientists (COTS)
"Transitional B cell cytokines predict renal allograft outcomes"
(Sci Transl Med. 2021 Feb 24;13(582):eabe4929. doi: 10.1126/scitranslmed.abe4929.)
In this article:
[The authors] prospectively examined the ratio of interleukin-10 (IL-10) to tumor necrosis factor-α (TNFα) produced by transitional-1 B cells (T1B) 3 months after transplantation as a predictive biomarker for clinical and subclinical renal allograft rejection and subsequent clinical course... Among high-risk patients without early rejection, 74% developed rejection later in the first year. In contrast, only 5% of low-risk patients had early and 5% late rejection... Biomarker high-risk patients exhibited progressively worse renal function and decreased 5-year graft survival compared to low-risk patients. Treatment of B cells with anti-TNFα in vitro augmented the IL-10/TNFα ratio, restored regulatory activity, and inhibited plasmablast differentiation. [The authors concluded that] the T1B IL-10/TNFα ratio was validated as a strong predictive biomarker of renal allograft outcomes and provides a rationale for preemptive therapeutic intervention with TNF blockade.
- Aravind Cherukuri, MBBS, PhD, MRCP • University of Pittsburgh, Pittsburgh, PA
- Aman Bajwa, PhD • University of Tennessee Health Science Center, Memphis, TN
- Olivia Martinez, PhD • Stanford University, Stanford, CA
- David Rothstein, MD • University of Pittsburgh, Pittsburgh, PA